Alumis Therapeutics is a startup based in All, most recent round IPO, 2 tracked investors.
Based in All, Alumis Therapeutics is a startup. Its most recent tracked round is IPO. Brouky records 2 investors associated with the company.
Alumis Inc. is developing next-generation targeted therapies for immune-mediated diseases, advancing a late-stage portfolio (including envudeucitinib) and using a proprietary data analytics platform to support precision therapeutic development.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.